Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) is set to announce second quarter earning results on Monday 10th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, EGRX to report 2Q20 income of $ 0.23 per share.
For the full year, analysts anticipate top line of $ 193.44 million, while looking forward to income of $ 2.02 per share bottom line.
Previous Quarter Performance
Eagle Pharmaceuticals, Inc. reported income for the first quarter of $ 0.84 per share, from the revenue of $ 46.02 million. The quarterly earnings reduced 16.83 percent while revenues down 2.23 percent compared with the same quarter last year.
According to street consensus, EGRX was expected to report 1Q20 income of $ 0.57 per share from revenue of $ 51.10 million. The bottom line results beat street analysts by $ 0.27 or 47.37 percent, at the same time, top line results fell short of analysts by $ 5.08 million or 9.94 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Eagle Pharmaceuticals, Inc.
Stock Performance
According to the previous trading day, closing price of EGRX was $ 47.00, representing a 39.05 % increase from the 52 week low of $ 33.80 and a 27.63 % decrease over the 52 week high of $ 64.94.
The company has a market capital of $ 643.20 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”EGRX” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Eagle Pharmaceuticals, Inc. will be hosting a conference call at 8:30 AM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.eagleus.com
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkins lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.
